Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Hong Kong (HSI) Healthcare Sector Analysis

UpdatedMar 31, 2026
DataAggregated Company Financials
Companies225
  • 7D7.7%
  • 3M2.2%
  • 1Y33.3%
  • YTD2.0%

Over the last 7 days, the Healthcare industry has risen 7.7%, driven by gains from Hansoh Pharmaceutical Group of 11%. Meanwhile, Xuanzhu Biopharmaceutical actually underperformed within the industry, shrinking 22% in the last week. In the last 12 months, the industry was up 33%. As for the next few years, earnings are expected to grow by 31% per annum.

Sector Valuation and Performance

Has the Hong Kong Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 01 Apr 2026HK$2.6tHK$1.5tHK$31.3b17.7x82x1.7x
Fri, 27 Feb 2026HK$2.5tHK$1.5tHK$34.1b15.3x74.5x1.7x
Sun, 25 Jan 2026HK$2.7tHK$1.4tHK$33.7b17.2x79.1x1.9x
Tue, 23 Dec 2025HK$2.5tHK$1.4tHK$33.7b17.4x73.4x1.8x
Thu, 20 Nov 2025HK$2.5tHK$1.4tHK$35.2b17.9x72.3x1.8x
Sat, 18 Oct 2025HK$2.6tHK$1.4tHK$34.1b17.7x75.6x1.9x
Mon, 15 Sep 2025HK$2.8tHK$1.5tHK$37.6b19.7x75.3x1.9x
Wed, 13 Aug 2025HK$2.5tHK$1.5tHK$35.7b17.5x70.2x1.7x
Fri, 11 Jul 2025HK$2.1tHK$1.5tHK$35.7b15.4x58.8x1.4x
Sun, 08 Jun 2025HK$1.9tHK$1.4tHK$33.4b14.4x58.2x1.3x
Tue, 06 May 2025HK$1.7tHK$1.4tHK$32.5b14.4x52.8x1.2x
Thu, 03 Apr 2025HK$1.7tHK$1.4tHK$33.8b14.4x50.1x1.2x
Sat, 01 Mar 2025HK$1.5tHK$1.4tHK$29.0b11.9x50.6x1x
Mon, 27 Jan 2025HK$1.3tHK$1.4tHK$29.2b11.4x44.1x0.9x
Wed, 25 Dec 2024HK$1.3tHK$1.4tHK$29.1b11.9x46.2x1x
Fri, 22 Nov 2024HK$1.3tHK$1.4tHK$28.7b12.1x46.9x0.9x
Sun, 20 Oct 2024HK$1.4tHK$1.4tHK$30.4b12.5x47.4x1x
Tue, 17 Sep 2024HK$1.3tHK$1.5tHK$30.8b11x41.2x0.9x
Thu, 15 Aug 2024HK$1.2tHK$1.4tHK$28.1b10.3x43.1x0.8x
Sat, 13 Jul 2024HK$1.2tHK$1.4tHK$27.5b10.5x45x0.9x
Mon, 10 Jun 2024HK$1.3tHK$1.4tHK$28.7b11.3x45.9x0.9x
Wed, 08 May 2024HK$1.4tHK$1.4tHK$28.9b12.2x48x1x
Fri, 05 Apr 2024HK$1.3tHK$1.4tHK$31.7b11.3x40.6x0.9x
Sun, 03 Mar 2024HK$1.4tHK$1.4tHK$26.6b11.9x50.9x1x
Tue, 30 Jan 2024HK$1.3tHK$1.4tHK$25.9b11.3x50.6x0.9x
Thu, 28 Dec 2023HK$1.5tHK$1.4tHK$26.4b12.5x57.2x1.1x
Sat, 25 Nov 2023HK$1.7tHK$1.4tHK$26.2b13x65.2x1.2x
Mon, 23 Oct 2023HK$1.5tHK$1.4tHK$24.6b11.9x61.8x1.1x
Wed, 20 Sep 2023HK$1.6tHK$1.4tHK$25.2b12.3x63.8x1.1x
Fri, 18 Aug 2023HK$1.6tHK$1.3tHK$11.8b13x132.8x1.2x
Sun, 16 Jul 2023HK$1.7tHK$1.4tHK$2.6b13.6x653.6x1.2x
Tue, 13 Jun 2023HK$1.7tHK$1.3tHK$3.0b14.5x573.3x1.3x
Thu, 11 May 2023HK$1.9tHK$1.4tHK$3.6b16x518.9x1.4x
Sat, 08 Apr 2023HK$1.9tHK$1.4tHK$4.5b13x420.2x1.4x
Price to Earnings Ratio

420.2x


Total Market Cap: HK$1.9tTotal Earnings: HK$4.5bTotal Revenue: HK$1.4tTotal Market Cap vs Earnings and Revenue0%0%0%
Hong Kong Healthcare Sector Price to Earnings3Y Average 112.5x202420252026
Current Industry PE
  • Investors are pessimistic on the Hong Kong Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 82.0x which is lower than its 3-year average PE of 113x.
  • The 3-year average PS ratio of 1.2x is lower than the industry's current PS ratio of 1.7x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 87% per year over the last three years.
  • Revenues for these companies have grown 2.5% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Hong Kong Healthcare sector?

HK Market1.44%
Healthcare7.72%
Biotech11.49%
Pharma6.44%
Medical Equipment5.33%
Life Sciences4.03%
Healthcare Services3.90%
Healthtech2.07%
Industry PE
  • Investors are most optimistic about the Life Sciences industry which is trading above its 3-year average PE ratio of 9.7x.
    • Analysts expect its future annual earnings growth (43.9%) to be largely in line with prior year's earnings growth.
Forecasted Growth
  • Analysts are most optimistic on the Healthtech industry, expecting annual earnings growth of 70% over the next 5 years.
  • This is better than its past earnings decline of 12% per year.
  • In contrast, the Pharma industry is expected to see its earnings grow by 17% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
3692 Hansoh Pharmaceutical GroupHK$35.4811.1%
+HK$21.4b		45.1%PE34.1x
9926 AkesoHK$130.208.5%
+HK$9.4b		51.4%PS34.6x
6990 Sichuan Kelun-Biotech BiopharmaceuticalHK$460.009.3%
+HK$9.1b		49.4%PS45.9x
1093 CSPC Pharmaceutical GroupHK$9.109.2%
+HK$8.8b		66.1%PE23.6x
3320 China Resources Pharmaceutical GroupHK$5.7829.9%
+HK$8.4b		11.4%PE7.9x

Latest News

1066
HK$3.75
Shandong Weigao Group Medical Polymer
7D
-17.0%
1Y
-38.0%

Shandong Weigao Group Medical Polymer Company Limited Just Missed EPS By 21%: Here's What Analysts Think Will Happen Next

Mar 31
Shandong Weigao Group Medical Polymer Company Limited Just Missed EPS By 21%: Here's What Analysts Think Will Happen Next
3692
HK$35.48
Hansoh Pharmaceutical Group
7D
11.1%
1Y
45.1%

Results: Hansoh Pharmaceutical Group Company Limited Beat Earnings Expectations And Analysts Now Have New Forecasts

Mar 31
Results: Hansoh Pharmaceutical Group Company Limited Beat Earnings Expectations And Analysts Now Have New Forecasts
2617
HK$66.50
TransThera Sciences (Nanjing)
7D
-4.5%
1Y
n/a
9926
HK$130.20
Akeso
7D
8.5%
1Y
51.4%
2276
HK$46.64
Shanghai Conant Optical
7D
-11.8%
1Y
69.9%
3933
HK$9.61
United Laboratories International Holdings
7D
-7.0%
1Y
-35.9%
3320
HK$5.78
China Resources Pharmaceutical Group
7D
29.9%
1Y
11.4%
2269
HK$33.02
WuXi Biologics (Cayman)
7D
-2.5%
1Y
23.2%

2269: Future Alliances And Compliance Wins Will Support A Fairly Valued Outlook

Analysts have revised their price target for WuXi Biologics (Cayman) to HK$33.34 from HK$32.64, based on updated assumptions for revenue growth, profit margins, future P/E levels and a slightly lower discount rate. What's in the News WuXi Biologics and Earendil Labs signed a collaboration for development and manufacturing of multiple bispecific and multispecific antibodies and ADC candidates, with WuXi Biologics providing end to end services from cell line development through GMP manufacturing to support global clinical development timelines (Client Announcements).
2096
HK$12.70
Simcere Pharmaceutical Group
7D
13.5%
1Y
53.9%

Simcere Pharmaceutical Group Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Mar 29
Simcere Pharmaceutical Group Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
1801
HK$84.90
Innovent Biologics
7D
4.1%
1Y
73.8%

Innovent Biologics, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 29
Innovent Biologics, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
2656
HK$103.90
160 Health International
7D
14.8%
1Y
n/a
1093
HK$9.10
CSPC Pharmaceutical Group
7D
9.2%
1Y
66.1%
2659
HK$91.30
Shanghai Bao Pharmaceuticals
7D
-6.4%
1Y
n/a
6990
HK$460.00
Sichuan Kelun-Biotech Biopharmaceutical
7D
9.3%
1Y
49.4%

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Mar 27
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990) Analysts Are Cutting Their Estimates: Here's What You Need To Know
2575
HK$29.32
Xuanzhu Biopharmaceutical
7D
-22.0%
1Y
n/a
2627
HK$29.32
Ab&B Bio-Tech JS
7D
-14.9%
1Y
n/a